Physician profile
Natasha M Von Roenn
NPI 1821297870
$64,776.82
in general payments reported to CMS, 2019-2025
7 companies · $43K in 2025
The $43K reported for 2025 was more than what 84% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,585 · 2021: $32.27 · 2022: $106 · 2023: $28.46 · 2024: $20K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Consulting Fee: $14K · Travel and Lodging: $3,774 · Food and Beverage: $2,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,685.50 |
| Consulting Fee | $14,325.00 |
| Travel and Lodging | $3,774.42 |
| Food and Beverage | $2,268.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $43,394.14 | 2024-2025 | Rezdiffra |
| Gilead Sciences, INC. | $19,580.13 | 2024-2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $1,658.54 | 2020-2022 | |
| Novo Nordisk INC | $64.54 | 2021-2022 | |
| Boston Scientific Corporation | $51.01 | 2025 | Cre Pro, Overstitch Endoscopic Suturing System |
| Medtronic, INC. | $28.46 | 2023 | Intellis Adaptivestim |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natasha Von Roenn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.